Stable Coronary Disease Clinical Trial
Official title:
A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage
The purpose of this study is to compare clopidogrel with ticagrelor which one has stronger anti-inflammation effect to protect against type 2 diabetes-induced vascular damage.
i- Verify the study inclusion and exclusion criteria at visit 1.
ii- Inform patients (verbally and in writing) and their caregivers (when considered
necessary and with the patient's consent) of the characteristics of the study and confirm
their agreement to participate by signing the informed consent document.
iii- Assist with patient assessment, record the information in the case report form. Based
on the data we get from the case report form, assign the patient to the experimental or
control group by stratified randomization.
ⅳ- At visit 2 to obtain blood sample from peripheral vessel and analyze the density of
CECs,sCD40L and hs-CRP by flow cytometry (FCM), ELISA and particle-enhanced turbidimetric
immunoassay.
ⅴ- All patients are given aspirin 100mg/qd orally and the experimental group given
ticagrelor 90mg/bid while the control group clopidogrel 75mg/qd for 30 days.
ⅵ- At visit 3 repeating step ⅳ and making comparison on numbers of CECs and CD40L between
the two groups, and finish a statistic analysis.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01122719 -
Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen
|
N/A | |
| Recruiting |
NCT05152888 -
The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk
|
Phase 4 | |
| Completed |
NCT02797158 -
Post TAVI Coronary REVASCularisation Guided by Myocardial Perfusion Imaging: a Prospective Open Label Pilot Study: The REVASC-TAVI Study
|
N/A |